Work

Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

Year: 2026
Type: article
Abstract: This study presents a Delphi consensus developed by the Headache Study Group of the Spanish Society of Neurology (GECSEN) to establish updated recommendations on key aspects of preventive migraine management. Given the high global burden of migraine and the emergence of novel preventive therapies—particularly OnabotulinumtoxinA and Calcitonin gene-related peptide (CGRP)-targeted treatments—there is a need to redefine therapeutic goals and optimize clinical decision-making. A nine-member Steering Committee defined 14 statements addressing five domains: candidate patient selection, therapeutic goals, treatment discontinuation, switching strategies, and combination therapy. A systematized literature review (171 selected publications) informed statement development. Eighty-eight migraine specialists participated in the first Delphi round and 48 in the second. Consensus was determined using the RAND/UCLA appropriateness method. Agreement was achieved for all 14 recommendations after two voting rounds. Preventive therapy is recommended in patients with ≥ 4 monthly migraine or moderate-to-severe headache days and relevant quality-of-life impairment. The ideal therapeutic goal is migraine freedom or minimization of attack frequency and intensity with improved quality of life. Optimal control is defined as < 4 monthly moderateto-severe headache days within three months. Treatment should generally be maintained for at least 12 months after achieving optimal control. Switching or combining preventive therapies—including CGRP monoclonal antibodies, gepants, and OnabotulinumtoxinA—may be considered in insufficient responders. This consensus proposes a treat-to-target strategy centered on patient-reported outcomes and residual disease burden, aiming to standardize preventive migraine care and improve long-term clinical outcomes.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,090
OpenAlex ID: W7233590655
FWCI:
Cites: 24
Cited by:
Related to: